MEDIPOST’s phase 1 clinical trial results for its injectable drug for knee osteoarthritis in Korea show improvements in safety and clinical symptoms

MEDIPOST completes the expansion of its GMP facilities for CARTISTEM, a stem cell therapy, and SMUP-IA-01, an injectable knee osteoarthritis treatment

MEDIPOST presents the development progress of its next-generation injectable drug for knee osteoarthritis in the Spring Conference of the Korean Orthopedic Surgeons Association

MEDIPOST requests approval for the phase 2 clinical trial in Korea of its next-generation injectable drug for knee osteoarthritis, SMUP-IA-01

MEDIPOST receives approval to proceed with phase 2 clinical trial in Korea for its next-generation injectable drug for knee osteoarthritis, SMUP-IA-01

MEDIPOST’s injectable drug for knee osteoarthritis, SMUP-IA-01, enters phase 2 clinical trials in Korea

MEDIPOST’s treatment for knee osteoarthritis, enters phase 3 clinical trials in Japan

MEDIPOST gears up to enter the global SMUP-IA-01 market based on clinical results in Korea

MEDIPOST’s 5-year follow-up of phase 3 clinical trial patients receives 2021 OJSM award

MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan

MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal

MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®